Sol-Gel Technologies Ltd. (FRA:4SG)

Market Cap	198.58M +941.5%
Revenue (ttm)	16.17M +62.0%
Net Income	-7.66M
EPS	-2.75
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	4
Open	65.50
Previous Close	68.00
Day's Range	65.50 - 65.50
52-Week Range	3.00 - 68.00
Beta	n/a
RSI	67.54
Earnings Date	Mar 9, 2026

About Sol-Gel Technologies

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has com...

• Industry: Pharmaceutical Preparations
• Founded: 1997
• Employees: 34
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4SG

Financial Performance

In 2024, Sol-Gel Technologies's revenue was $11.54 million, an increase of 642.47% compared to the previous year's $1.55 million. Losses were -$10.58 million, -61.16% less than in 2023.

Financial numbers in USD